Skip to content
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Rheumatology

How Often Should EGPA Bloodwork Be Done in Remission?

At a Glance

People with eosinophilic granulomatosis with polyangiitis (EGPA) often have clinic visits and routine bloodwork every 3 to 6 months when remission is stable, but the schedule should be personalized based on prior organ involvement, medicines, and relapse risk.

Remission in Eosinophilic Granulomatosis with Polyangiitis (EGPA) means there is no current evidence of active vasculitis (blood vessel inflammation). However, it does not mean your condition is permanently cured, and you may still experience symptoms from prior organ damage or persistent asthma [1][2]. Because EGPA can flare again (a relapse), ongoing monitoring is a critical part of your long-term survivorship.

There is no single, universal schedule that applies to everyone in remission. Current guidelines emphasize that your follow-up schedule must be individualized based on which organs were previously involved, your current treatments, and your specific risk of relapse [3][4][5]. However, as a general example, specialists often recommend seeing your vasculitis care team and getting routine lab work every 3 to 6 months once your disease is stable [6]. You may need more frequent visits if you are tapering off medications or if you have a history of severe organ involvement.

Routine Clinic Visits and Bloodwork

During your routine visits, your doctor will check for physical symptoms across the systems EGPA commonly affects, including your lungs, sinuses, skin, peripheral nerves (checking for numbness or weakness), and gastrointestinal tract [6]. Because some organ damage can occur silently, you will also undergo routine laboratory testing. You can typically expect:

  • Complete Blood Count (CBC) with differential: This checks your levels of eosinophils (a type of white blood cell). However, a normal eosinophil count does not rule out active EGPA or guarantee that a future relapse will not occur, especially if you are taking steroids or biologic therapies [7][8].
  • Inflammatory markers (CRP and ESR): Tests for C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) measure general inflammation. Like eosinophils, these markers can be suppressed by treatments and are not used alone to declare you are flare-free [8].
  • Kidney function tests and urinalysis: Routine follow-up often includes checking for hidden kidney damage or the presence of protein and blood in the urine. This is done for all patients, but monitoring is especially close if you had prior kidney involvement or were ANCA-positive at diagnosis [9][10].

ANCA Testing and Biomarkers

If you tested positive for ANCA (antineutrophil cytoplasmic antibodies) when you were first diagnosed, your doctor may monitor these levels periodically [11]. However, serial ANCA testing has limited predictive value. Some patients have ANCA increases without a flare, and others experience a relapse while their ANCA levels remain perfectly stable [10][12]. Laboratory tests are always interpreted alongside your symptoms, physical exam, and organ-specific tests.

Medication Safety Monitoring

Part of your follow-up care is ensuring your maintenance medications aren’t causing harmful side effects. Never stop or reduce your immunosuppressants or steroids on your own, as abrupt withdrawal can be dangerous and prompt a flare.

  • Biologics and Immunosuppressants: If you take rituximab, your doctor will likely monitor your immunoglobulins (antibodies) because the drug can cause them to drop, increasing your risk of infections (hypogammaglobulinemia) [8]. Other drugs require their own monitoring, such as routine liver enzyme or white blood cell checks [13].
  • Glucocorticoids (Steroids): Long-term steroid use carries risks. Your doctor will likely monitor your blood pressure, blood glucose, bone health, and risk for eye conditions (like cataracts or glaucoma) as part of your safety follow-up [4].

Imaging and Organ-Specific Tests

In general, research does not support indiscriminate, repeated CT or MRI scans for every asymptomatic patient in remission [14]. Test selection depends entirely on your clinical context:

  • Heart Monitoring (An Exception): Because EGPA can cause silent but serious heart damage, proactive cardiac evaluation is often recommended even without symptoms. Your doctor may order baseline or periodic tests like an electrocardiogram (ECG), echocardiogram, or a cardiac MRI to ensure your heart remains healthy [15][16].
  • Lungs and Sinuses: If you develop worsening asthma, breathlessness, or sinus issues, your doctor may order pulmonary function tests (PFTs), a chest X-ray, or a sinus CT scan [6][1]. However, worsening respiratory symptoms do not automatically mean your vasculitis has returned—they could simply be due to persistent asthma, an infection, or allergies [1].

Urgent Warning Signs: When to Seek Immediate Care

While your routine appointments are scheduled every few months, some symptoms require immediate medical attention. Go to the emergency room or contact your care team urgently if you experience:

  • New or worsening chest pain, fainting, or sustained palpitations
  • Severe or rapidly worsening shortness of breath
  • Coughing up blood
  • Sudden weakness, numbness, or “foot drop” (difficulty lifting the front part of the foot)
  • Major or sudden vision changes
  • Severe abdominal pain, or black/bloody stools
  • Markedly reduced urine output or new visible blood in your urine
  • Fever or signs of severe infection while on immunosuppressants

Common questions in this guide

How often do people with EGPA usually have bloodwork after reaching remission?
There is no single schedule for everyone. When EGPA is stable, specialists often arrange clinic visits and routine laboratory testing every 3 to 6 months, with more frequent follow-up during medication tapering or after severe organ involvement.
What blood tests are commonly used to monitor EGPA in remission?
Follow-up commonly includes a complete blood count with an eosinophil count, inflammation tests such as CRP and ESR, and kidney function testing. A urine test may also check for hidden blood or protein, and the results are interpreted together with symptoms and the physical examination.
Does a normal eosinophil count mean that EGPA cannot flare?
No. Steroids and biologic medicines can suppress eosinophil levels, so a normal result does not rule out active EGPA or guarantee that a future relapse will not occur. Doctors use symptoms, examination findings, and other tests as well as the eosinophil count.
Can ANCA levels predict whether EGPA will relapse?
ANCA testing may be useful in some patients, but repeated ANCA levels do not reliably predict a flare. Some people have a rise without a relapse, while others relapse without a significant change, so results must be considered with symptoms and organ-specific testing.
Why might I need heart tests while my EGPA is in remission?
EGPA can cause heart problems without obvious symptoms, so a clinician may recommend a baseline or periodic ECG, echocardiogram, or cardiac MRI. The need and timing depend on your medical history and the judgment of your care team.
What medication safety checks may be needed during EGPA remission?
Rituximab may require immunoglobulin monitoring because it can lower infection-fighting antibodies, while other immunosuppressants may require liver enzyme or white blood cell checks. Long-term steroids may also require monitoring of blood pressure, blood glucose, bone health, and eye health.
Which symptoms should prompt urgent care during EGPA remission?
Seek urgent medical help for new chest pain, fainting, severe breathlessness, coughing up blood, sudden weakness or numbness, major vision changes, severe abdominal pain, black or bloody stools, markedly reduced urine, visible blood in the urine, or signs of a serious infection. Do not wait for a routine appointment if these symptoms occur.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on the organs that were involved during my initial flare, what specific tests do I need at my routine visits?
  2. 2.What is my personalized schedule for bloodwork and clinic visits now that I am in remission?
  3. 3.What routine safety labs are required for the specific maintenance medications I am currently taking?
  4. 4.Do I need a baseline or follow-up cardiac evaluation, such as an ECG, echocardiogram, or cardiac MRI, even if I have no chest symptoms?
  5. 5.Who should I contact first (rheumatologist, pulmonologist, etc.) if my asthma or sinus symptoms worsen?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (16)
  1. 1

    Eosinophilic granulomatosis with polyangiitis: case report and literature review.

    Alam V, Nanzer AM

    Breathe (Sheffield, England) 2022; (18(4)):220170 doi:10.1183/20734735.0170-2022.

    PMID: 36865937
  2. 2

    Intravenous immunoglobulin for chronic residual peripheral neuropathy in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome): a multicenter, double-blind trial.

    Koike H, Akiyama K, Saito T, et al.

    Journal of neurology 2015; (262(3)):752-9 doi:10.1007/s00415-014-7618-y.

    PMID: 25577176
  3. 3

    2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

    Chung SA, Langford CA, Maz M, et al.

    Arthritis & rheumatology (Hoboken, N.J.) 2021; (73(8)):1366-1383 doi:10.1002/art.41773.

    PMID: 34235894
  4. 4

    Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis.

    Emmi G, Bettiol A, Gelain E, et al.

    Nature reviews. Rheumatology 2023; (19(6)):378-393 doi:10.1038/s41584-023-00958-w.

    PMID: 37161084
  5. 5

    2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

    Chung SA, Langford CA, Maz M, et al.

    Arthritis care & research 2021; (73(8)):1088-1105 doi:10.1002/acr.24634.

    PMID: 34235880
  6. 6

    Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis.

    Teixeira V, Mohammad AJ, Jones RB, et al.

    RMD open 2019; (5(1)):e000905 doi:10.1136/rmdopen-2019-000905.

    PMID: 31245051
  7. 7

    Refractory diffuse alveolar hemorrhage caused by eosinophilic granulomatosis with polyangiitis in the absence of elevated biomarkers treated successfully by rituximab and mepolizumab: A case report.

    Shiroshita A, Nakashima K, Motojima S, Aoshima M

    Respiratory medicine case reports 2019; (26()):112-114 doi:10.1016/j.rmcr.2018.12.010.

    PMID: 30603598
  8. 8

    Rituximab as Induction Therapy in Eosinophilic Granulomatosis with Polyangiitis Refractory to Conventional Immunosuppressive Treatment: A 36-Month Follow-Up Analysis.

    Thiel J, Troilo A, Salzer U, et al.

    The journal of allergy and clinical immunology. In practice 2017; (5(6)):1556-1563 doi:10.1016/j.jaip.2017.07.027.

    PMID: 28916432
  9. 9

    ANCA-associated vasculitis with renal involvement.

    Binda V, Moroni G, Messa P

    Journal of nephrology 2018; (31(2)):197-208 doi:10.1007/s40620-017-0412-z.

    PMID: 28560688
  10. 10

    Long-Term Followup of a Multicenter Cohort of 101 Patients With Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss).

    Durel CA, Berthiller J, Caboni S, et al.

    Arthritis care & research 2016; (68(3)):374-87 doi:10.1002/acr.22686.

    PMID: 26315340
  11. 11

    International Consensus on Antineutrophil Cytoplasm Antibodies Testing in Eosinophilic Granulomatosis with Polyangiitis.

    Moiseev S, Bossuyt X, Arimura Y, et al.

    American journal of respiratory and critical care medicine 2020; (202(10)):1360-1372 doi:10.1164/rccm.202005-1628SO.

    PMID: 32584187
  12. 12

    Hypertrophic Pachymeningitis Development in Eosinophilic Granulomatosis with Polyangiitis at Relapse of Disease: A Case-Based Review.

    Kiyohara M, Shirai T, Nishiyama S, et al.

    The Tohoku journal of experimental medicine 2022; (256(3)):241-247 doi:10.1620/tjem.256.241.

    PMID: 35321968
  13. 13

    Interferon-α for Induction and Maintenance of Remission in Eosinophilic Granulomatosis with Polyangiitis: A Single-center Retrospective Observational Cohort Study.

    Seeliger B, Förster M, Happe J, et al.

    The Journal of rheumatology 2017; (44(6)):806-814 doi:10.3899/jrheum.160907.

    PMID: 28412705
  14. 14

    When inflammation is not just inflammation-A review of systemic diseases of the nose and sinuses part 2: Granulomatosis with polyangiitis and eosinophilic granulomatosis with polyangiitis.

    Cler SJ, Ogden MA, Farrell NF, et al.

    American journal of otolaryngology 2024; (45(3)):104207 doi:10.1016/j.amjoto.2023.104207.

    PMID: 38176206
  15. 15

    Cardiac Involvement in Eosinophilic Granulomatosis with Polyangiitis.

    Srikantharajah M, Gopalan D, Wilson-Morkeh H, et al.

    Current cardiology reports 2025; (27(1)):109.

    PMID: 40632386
  16. 16

    [Cardiac involvement in Churg-Strauss syndrome].

    Brucato A, Maestroni S, Masciocco G, et al.

    Giornale italiano di cardiologia (2006) 2015; (16(9)):493-500 doi:10.1714/1988.21524.

    PMID: 26418389

This page is for informational purposes only and does not constitute medical advice about EGPA. Your rheumatologist and other specialists should set your monitoring schedule and interpret results in the context of your symptoms and treatment.

Get notified when new evidence is published on Eosinophilic granulomatosis with polyangiitis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.